Marsh & McLennan Companies, Inc.
MRSH · NYSE
Company research
Marsh & McLennan Companies, Inc. (NYSE: MRSH) is the world's largest insurance broker and a leading global professional services firm headquartered in New York City, founded in 1871 and employing approximately 95,000 professionals across 130 countries. The company provides advisory services and insurance solutions in the areas of risk, strategy, and human capital through its four market-leading subsidiaries: Marsh (insurance brokerage and risk management), Guy Carpenter (reinsurance intermediary and advisory), Mercer (health, wealth, and career consulting), and Oliver Wyman (management, economic, and brand consulting). Marsh & McLennan operates through two core segments — Risk and Insurance Services, which accounts for approximately 63% of revenues, and Consulting, contributing the remaining 37% — serving 95% of Fortune 1000 companies with annual revenues exceeding $24 billion. Under the leadership of CEO John Q. Doyle, the firm maintains a dominant market position, holding an estimated 13–15% share of the global commercial insurance brokerage market, making it a premier financial services powerhouse in the Insurance Brokers industry.
Research reports
Ultra Stock Analysis Pro · April 19, 2026Marsh & McLennan Companies, Inc. (MRSH) – Comprehensive Analyst Report
This AI-assisted technical and fundamental report assigns a hold rating to MRSH, framing roughly 15.9% upside to the $203.67 analyst consensus target while emphasizing a 52.9% historical win rate, moderate growth, and very high (92.3%) institutional ownership. It highlights earnings volatility, weak current trend strength, and modest risk/reward (1.06:1), recommending disciplined ATR-based stop-loss management and patience for stronger technical “confluence” signals before adding exposure.
StockStory (independent Equity Research Boutique) · March 30, 2026Marsh & McLennan (MRSH) Research Report: Q4 CY2025 UpdateStockStory characterizes Marsh & McLennan as a high-quality, cash-generative professional services firm and explicitly states “we’d invest” at around 16.8x forward P/E, citing a massive $26.98B revenue base, strong adjusted operating margins, and robust free cash flow and ROIC as drivers of long-term outperformance. The report points to a consensus one‑year price target of $207.20 (about 21.8% upside) alongside decelerating near‑term revenue growth and advises monitoring demand headwinds, leverage, and execution while still viewing the current valuation as attractive for a buy‑and‑hold investor.
Henry Fund, Henry B. Tippie College Of Business, University Of Iowa (university Student-managed Fund) · September 29, 2025Marsh & McLennan Companies, Inc. (MMC, now MRSH) – Henry Fund Equity ResearchThis university fund report initiates a sell rating on Marsh & McLennan (then‑ticker MMC, now MRSH) with a $185 target price, arguing that slowing organic growth in core Marsh and Guy Carpenter segments, moderating insurance pricing tailwinds, and limited remaining scope for margin expansion leave the stock’s valuation exposed and imply around 7.7% downside from the then‑current price. It flags risks from earnings compression, acquisition integration and synergy realization, and macro/insurance‑cycle normalization, while acknowledging possible offsetting upside from AI-driven data advantages, a hardening market, and successful M&A but treats these as secondary to the downside skew.